ABVE vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

ABVE

49.0
AI Score
VS
ABVE Wins

CLOV

46.9
AI Score

Investment Advisor Scores

ABVE

49score
Recommendation
HOLD

CLOV

47score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ABVE CLOV Winner
Forward P/E 0 81.9672 Tie
PEG Ratio 0 0 Tie
Revenue Growth -45.0% 62.0% CLOV
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 49.0/100 46.9/100 ABVE
Profit Margin -23.4% -2.6% CLOV
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

ABVE 1M: -79.2% · 3M: -91.4% CLOV 1M: -14.5% · 3M: +63.2%

Current Technical Phase

ABVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -29.1%), weak momentum, RSI 28

RSI (14): 28.0 · Price: $0.11

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $4.33

Fundamentals Snapshot

Metric ABVE CLOV
Market Cap
Forward P/E 0.0 43.3
Trailing P/E
Revenue (TTM)
Revenue Growth -0.5% 0.6%
Gross Margin 0.0% 0.2%
Operating Margin -0.2% 0.0%
EPS -1.75 -0.12
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ABVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.